Alert

Alert Pro Chart

SELLAS Life Sciences Grou... (SLS)

NasdaqCM: SLS · Real-Time Price · USD

11.77

+0.72 (6.52%)

At close: Aug 12, 2026, 3:59 PM

11.79

+0.19%

After-hours: 7:25 PM

6.52% (1D)

Bid	8.93
Market Cap	2.31B
Revenue (ttm)	n/a
Net Income (ttm)	-29.46M
Beta	2.49
EPS (ttm)	-0.22
PE Ratio (ttm)	n/a
Forward PE	-94.16
P/B (ttm)	19.88
P/S (ttm)	n/a
Earnings Date	Nov 11, 2026

Ask	12.05
Volume	7,734,493
Avg. Volume (20D)	9,793,182
Open	11.92
Previous Close	11.05
Day's Range	11.50 - 12.45
52-Week Range	1.39 - 15.88
Analyst	n/a
Price Target	27.5 (133.64%)
Dividends	n/a
Ex-Dividend Date	n/a

About SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration w...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 12, 2008

Employees 13

Stock Exchange NasdaqCM

Ticker Symbol SLS

Website https://sellaslifesciences.com

Full Company Profile

Financial Performance

In 2025, SELLAS Life Sciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.86M, a decrease of -13.01%.

Financial Statements

Analyst Forecast

According to 2 analyst ratings, the average rating for SLS stock is "null". The 12-month stock price forecast is 27.5, which is upside of 133.64% from the latest price.

Stock Forecasts

Earnings Surprise

New

SELLAS Life Sciences has released their quarterly earnings on Aug 11, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.05 misses estimates by -0.01, with 28.57% YoY growth.

Next Earnings Release

SELLAS Life Sciences Group Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

3 hours ago · Stocktwits

Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential

Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

19 hours ago · Stocktwits

SLS Stock Flat After-Hours Despite Narrower Per-Share Q2 Loss — Investors Eye End Of GPS Quiet Period

The biotech, focused on novel cancer therapies, reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30.

1 day ago · Stocktwits

SLS Stock Rebounds Premarket After Worst Day In 3 Weeks — Retail Awaits ‘Very Special’ Earnings Update

Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05 previously.

1 week ago · Stocktwits

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

1 week ago · Simply Wall St.

SELLAS Life Sciences Group (SLS) Is Up 11.2% After Daiwa Boosts Stake And REGAL Nears Readout - Has The Bull Case Changed?

In recent months, Daiwa Securities very sharply increased its stake in SELLAS Life Sciences Group by 100,300 shares, while SELLAS reported that its Phase 3 REGAL trial in acute myeloid leukemia had re...

Page 1 of 2